drugset / Trial / NCT07367815
Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease
Non-randomizedSequentialOpen-labelTreatment
Summary
A3D is a phase I/II clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a dose escalation protocol.
Timeline
- Start
- 2026-05-07
- Primary completion
- 2029-05-01
- Completion
- 2029-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CellREADY® drug product | Unknown | 50 cells | Intravenous |
| Subject | CellREADY® drug product | Unknown | 100 cells | Intravenous |